Comparative efficacy and cognitive safety of magnetic seizure therapy and electroconvulsive therapy in major depressive disorder: a systematic review and meta-analysis - Summary - MDSpire
Advertisement
Comparative efficacy and cognitive safety of magnetic seizure therapy and electroconvulsive therapy in major depressive disorder: a systematic review and meta-analysis
To compare the antidepressant efficacy and cognitive safety of Magnetic Seizure Therapy (MST) versus Electroconvulsive Therapy (ECT) for Major Depressive Disorder (MDD), emphasizing the importance of cognitive safety.
Key Findings:
MST and ECT had comparable clinical response (RR = 1.10, 95% CI: 0.94-1.27) and remission rates (RR = 1.04, 95% CI: 0.72-1.50).
MST was superior in preserving cognitive function (SMD = 1.19, p=0.005) and enabling faster reorientation (MD = -16.72 min, p<0.00001).
MST reduced overall adverse event risk (OR = 0.23, p<0.00001), particularly for memory loss, headache, and muscle pain.
Seizure durations were shorter with MST.
Interpretation:
MST provided significantly better cognitive safety and tolerability compared to ECT, despite comparable efficacy in response and remission rates, highlighting its potential as a preferred option for patients concerned about cognitive side effects.
Limitations:
Heterogeneity in stimulation parameters and comparator ECT protocols may affect the generalizability of the findings.
Variability in outcome measures across studies could impact the reliability of comparisons.
Conclusion:
MST is a valuable alternative for MDD patients, especially when cognitive side effects are a primary concern, suggesting a need for further exploration in clinical settings.
The partner in the next room, the hormone in the blister pack, the cat on the couch, the minute-long chair stand. Several new studies suggest the factor shaping outcomes may be the one clinicians aren’t routinely measuring.
